Related Experiment Video
Updated: Aug 13, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
Published on: November 2, 2014
Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma
Jie Qing Zhang1, Bing Bing Zhao1, Mao Mao Wang1
1Department of Gynecologic Oncology, Guangxi Medical University Cancer Hospital, Nanning, China.
Abstract:
Ovarian carcinosarcoma (OCS) is a rare, highly aggressive and rapidly progressing malignant tumor with an extremely poor prognosis. So far, due to the low incidence of OCS, there are no large-scale prospective studies exploring the standard care of OCS patients. There is no uniform and effective treatment for OCS. Within the development of precision medicine, targeted therapies (such as PARP inhibitors) have been widely used in epithelial ovarian cancer and various other solid tumors. Here, we report a BRCAwt patient with advanced OCS who experienced a second and a third cytoreductive surgery in June 2017 and October 2019 and has been on niraparib maintenance therapy for more than 20 months after receiving second-line and third-line chemotherapy.
Related Concept Videos
Treatment Resistant Cancers
Treatment Resistent Cancers

